国产长春瑞滨联合顺铂治疗晚期非小细胞肺癌  

Clinical study of vinorelbine combined with cisplatin in the treatment of non-small cell lung cancer

作　　者：孙炜[1] 蔡礼鸣[1] 毛曼[1] 张芳[1] 

机构地区：[1]无锡市第四人民医院呼吸内科,江苏无锡214062

出　　处：《实用医药杂志》2006年第10期1163-1165,共3页Practical Journal of Medicine & Pharmacy

摘　　要：目的观察国产抗肿瘤药物长春瑞滨(盖诺)和顺铂联合化疗治疗晚期非小细胞肺癌的疗效。方法采用NP方案治疗晚期非小细胞肺癌(NSCLC)38例,男29例,女9例。腺癌28例,鳞癌8例,大细胞癌2例。Ⅲ期20例,Ⅳ期18例；初治25例,复治13例。结果部分缓解(PR)16例,稳定(SD)13例,进展(PD)9例。总有效率为42%。每周盖诺≥25mg/m^2的毒性反应主要是暂时性骨髓抑制,主要表现白细胞数下降86．8%,其中Ⅲ、Ⅳ度为18．4%；局部静脉炎发生率为52．6%。结论国产长春瑞滨(盖诺)替代进口诺维本+顺铂治疗晚期NSCLC可行,其疗效、毒副反应与诺维本相近。Objective To evaluate the result of combination chemotherapy with China-made vinorelbine （GaiNuo） plus cisplatin （DDP） in the treatment of non-small cell lung cancer （NSCLC）.Methods 38 patients with advanced NSCLC were enrolled in this study .The median age of the patients w as 61 years. Adenocarinoma was the most common type of malignancy.20 patients had stageⅢm of the disease and 18 had stage Ⅳ.25 patients had no prior chemotherapy and 13 patients received previous chemotherapy. Results Partial response was observed in 16 patients with an overall response rate of 42%.The dose limiting toxicity was neutropenia which was seen in all treated cases （18.4% in grades Ⅲ and Ⅳ）.The local venous toxicity was observed in 52.6% of the patients.When being ≥25mg/m^2·week,the adverse reaction was temporary bone marrow suppression.Conclusion A high response rate could be obtained in advanced NSCLC treated by GaiNuo plus DDP,China-made GaiNuo could substitute the oversea drug.

关 键 词：肺肿瘤/药物疗法 癌 非小细胞肺癌 药物疗法 长春瑞滨 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]